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ABSTRACT: Lung cancer kills more humans than any other cancer and multidrug resistance 
(MDR) in cancer stem-like cells (CSC) is emerging as a reason for failed treatments. One 
concept which addresses this root cause of treatment failure is the utilization of nanoparticles to 
simultaneously deliver dual drugs to cancer cells with synergistic performance, easy to envision 
 hard to achieve. It is challenging to simultaneously load drugs of highly different 
physicochemical properties into one nanoparticle, release kinetics may differ between drugs and 
general requirements for biomedical nanoparticles apply. Here self-assembled nanoparticles of 
amphiphilic carboxymethyl-hexanoyl chitosan (CHC) were shown to present nano-
microenvironments enabling simultaneous loading of hydrophilic and hydrophobic drugs. This 
was expanded into a dual-drug nano-delivery system to treat lung CSC. CHC nanoparticles were 
loaded/chemically modified with the anticancer drug cisplatin and the MDR-suppressing Chinese 
herbal extract demethoxycurcumin, followed by biofunctionalization with CD133 antibody for 
enhanced uptake by lung CSC, all in a feasible one-pot preparation. The nanoparticles were 
characterized with regard to chemistry, size, zeta potential and drug loading/release. 
Biofunctionalized and non-functionalized nanoparticles were investigated for uptake by lung 
CSC. Subsequently the cytotoxicity of single and dual drugs, free in solution or in nanoparticles, 
was evaluated against lung CSC at different doses. From the dose response at different 
concentrations the degree of synergy was determined through Chou-
biofunctionalized nanoparticles promoted synergistic effects between the drugs and were highly 
effective against MDR lung CSC. The efficacy and feasible one-pot preparation suggest 
preclinical studies using relevant disease models to be justified. 
KEYWORDS: biodegradable chitosan nanoparticle; CD133; CDDP; dual-drug delivery; 
synergistic effect  
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1. Introduction 
Amphiphilic carboxymethyl-hexanoyl chitosan (CHC) was modified through a feasible one-
pot preparation to achieve antibody-functionalized dual-drug nanoparticles for simultaneous 
delivery of demethoxycurcumin (DMC) and cisplatin (CDDP). It was hypothesized that the 
simultaneous intracellular delivery and co-localization of the drugs mediated by the 
nanoparticles would result in greatly enhanced synergistic effect against lung cancer stem-like 
cells (CSC) and that this nanomedical technology would thus show potential for combinatorial 
cancer therapy, an approach already employed in treatment of lung cancer by clinicians using 
free drugs [1]. 
Among cancers, lung cancer remains a leading killer [2]. Treatment of non-small cell lung 
cancer (NSCLC) is particularly important from a healthcare perspective, as it combines high 
prevalence (about 85% of lung cancer cases) with high mortality [2]. When the cancer has 
entered the stage at which complete removal by surgery is difficult, chemotherapy, targeted 
drugs or immunotherapy is commonly employed [2]. Unfortunately the 5-year survivability is 
quite low, even with treatment [2]. The difficulty in killing of the cancer and the resulting low 
survival rate may be due to CSC [3, 4]. The role of CSC is just beginning to be understood, but 
they are thought to play critical roles in metastasis and cancer relapse after treatment, while also 
presenting multidrug resistance (MDR) features [3, 4]. It is thus critical to develop improved 
treatments to overcome MDR and effectively kill the CSC. 
Dual-drug administration has been discussed for years as a means to improved cancer 
treatment with potential benefits such as reduced side-effects due to lowering of drug 
concentrations and reduction of MDR. Although nanoparticle-based dual-drug delivery seems 
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highly promising, there are challenges in terms of complex production processes, low 
encapsulation efficiencies and unfavorable release profiles of the different drugs [5]. 
In the clinic, CDDP is a first-line drug for NSCLC treatment and combinations with other 
drugs are commonly employed [1]. However, resistance of cancers towards CDDP is commonly 
observed through cysteine-rich protein blocking [6, 7] and responses from the NF- -
upregulated MDR CD133 signaling pathway, which is highly active in CSC [3, 6, 8-10]. Cells 
with upregulated CD133 present resistance to treatment, self-renewal capability, fast DNA repair 
and overexpression of multidrug resistance protein 1 (MRP1) and breast cancer resistance 
protein 1 (BCRP), among others [3, 8, 10]. Curcuminoids, a traditional Chinese medicine herbal 
extract, have been reported to downregulate NF- -related proteins, promote 
apoptosis through inactivation of Bcl-2 [11, 12] and reverse CDDP resistance in lung cancer 
[13]. Recently, free curcumin has also been shown to act in synergy with CDDP and 
CDDP/polymer-conjugate nanoparticles to achieve improved efficacy against CDDP-resistant 
ovarian cancer cells [14]. DMC is a curcuminoid with better stability in blood and under basic 
condition compared to the commonly used curcumin [15]. Therefore, this work focused on 
feasible one-pot preparation of CD133-antibody dressed nanoparticles for simultaneous 
intracellular delivery of the well-proven hydrophilic anticancer drug CDDP and the hydrophobic 
curcuminoid DMC to overcome MDR in CSC through enhanced synergistic effects. In vitro 
evaluation of cell internalization and effectiveness against MDR lung cancer cells was carried 
out using A549-ON, a stable cell line presenting stem-like characteristics and overexpression of 
CD133, prepared by transfection of human A549 lung adenocarcinoma cells using a lentiviral 
infection system with vectors encoding Oct4 and Nanog cDNA [9]. 
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2. Methods 
2.1. Materials 
Cis- diammine platinum(II) dichloride (cisplatin, CDDP), o-phenylenediamine (OPDA), 
dimethyl sulfoxide (DMSO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 2-propanol, 
sodium hydroxide, chloroacetic acid, deuterium oxide (D2O), and phosphate buffered saline 
(PBS) were purchased from Sigma-Aldrich. Carboxymethyl-hexanoyl chitosan (CHC) was 
purchased from Advanced Delivery Technologies, Inc. PSVue®480 was purchased from 
Molecular Targeting Technologies, Inc. N,N-dimethylformamide (DMF) was purchased from 
Aencore. Demethoxycurcumin (DMC) was a courteous gift from China Medical University 
(Taiwan). The CD-133 antibody was purchased from Genetex. All other chemical reagents in the 
study were of analytical grade and were used as received without further purification. A549-ON, 
a stable cell line with stem-like characteristic and overexpression of CD133, prepared by 
transfecting human A549 lung adenocarcinoma cells using a lentiviral infection system with 
vectors encoding Oct4 and Nanog cDNA [9], were kindly provided by Professor Shih-Hwa 
Chiou (Yang Ming University, Taiwan). The reader is referred to the given reference for detailed 
cell characteristics and preparation protocol. 
2.2. Preparation of CHC/CDDP and CHC/DMC Nanoparticles: 
CHC/CDDP and CHC/DMC nanoparticles were prepared by mixing 0.4 mL of CDDP or 
DMC (1 mg/mL) in 1% DMSO in ddH2O with 1 mg of CHC and 1.6 mL pH 11 ddH2O. The pH 
of the resulting solution was about 7 and the particles were mixed on a magnetic stirrer for 12 h 
to allow self-assembly into drug loaded nanoparticles. Subsequently, the sample was placed into 
Amincon centrifugal filter and centrifuged at 5000 rpm for 30 minutes to remove unloaded drug. 
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The gel-like nanoparticle-concentrate was dispersed ddH2O to required concentrations. 
Encapsulation efficiency (EE) was measured, as described in section 2.6, before use of 
nanoparticles to ensure use of correct drug concentration. 
2.3. Analysis of CHC/CDDP Interactions: 
Fourier transformed infrared spectroscopy (FT-IR) was conducted on a Spectrum 100 (Perkin 
Elmer) as follows: 1 mL samples nanoparticle samples were concentrated using Amicon 
ddH2O was added to 
disperse the nanoparticle-concentrates. The nanoparticle dispersions were applied on silicon 
wafers, taking care to avoid bubble formation, and were dried at 50 oC. Spectra were recorded 
with a resolution of 1 cm-1 between 4000 and 400 cm-1.  
Samples for X-ray photoelectron spectroscopy (XPS) analysis were prepared as follows: 
Nanoparticle dispersions were freeze-dried for one day to obtain fiber-like samples that were 
mounted on silicon wafers. CDDP powder was mounted as delivered onto the silicon wafer. The 
samples were briefly sputtered with Au to improve the electrical conductivity and were analyzed 
for elemental composition using a Microlab 350 X-ray photoelectron spectrometer (VG 
 
Samples were prepared for platinum nuclear magnetic resonance spectroscopy (195Pt NMR) by 
freeze-drying of 10 mL of dissolved CDDP or dispersed nanoparticles for one day, followed by 
dissolution/dispersion in 1 mL of D2O. 195Pt NMR spectra were recorded using a 600 MHz 
Mercury NMR spectrometer (Varian).  
2.4. Preparation of CHC/DMC-CDDP Nanoparticles: 
CHC/CDDP-DMC nanoparticles were prepared by mixing 0.4 mL of DMC (X µg/mL) in 1% 
DMSO in ddH2O with 1 mg of CHC and 1.2 mL pH 9 ddH2O, followed by addition of 0.4 mL of 
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CDDP (Y µg/mL) in 1% DMSO in ddH2O. For characterizations and in vitro release X and Y = 
1000. To investigate the effect of different drug concentrations on in vitro cytotoxicity the drug 
loading was modified to achieve desired concentrations (X, Y = 50, 750; 100, 1500; 150, 2250; 
150, 3000; 200, 3000). The pH of the resulting solution was about 7 and the particles were mixed 
on a magnetic stirrer for 12 h to allow self-assembly into drug loaded nanoparticles. Further 
preparation was performed as for CHC/CDDP nanoparticles, described above. Before use the EE 
was measured for each preparation, as described in section 2.6, to ensure use of correct drug 
concentrations. 
2.5. Modification with CD133 Antibodies: 
After preparing CHC/CDDP-DMC nanoparticles, as described above, but before the 
centrifugation-filtration step to separate nanoparticles from free drug, 1 µL of anti-CD133 
antibodies (1 mg/mL in ddH2O) was added to the solution. The mixture was stirred at 4 oC for 
one hour, after which 0.05 mL of EDC solution (0.1%, w/v) was slowly added over 4 hours to 
crosslink between carboxyl groups and amine groups. The CHC/CDDP-DMC/Anti-CD133 
nanoparticles were subsequently separated from free drug and unreacted reagents using an 
Amicon centrifugal filter at 5000 rpm for 30 minutes. As for non-targeted nanoparticles, the gel-
like concentrate was dispersed in ddH2O to a final volume of 2 mL. 
2.6. Encapsulation Efficiency of CHC-Based Nanoparticles: 
The drug EE was calculated using Eq 1: 
EE%=  x 100%          (1) 
where A is the amount of drug loaded in nanoparticles and B is the total amount of added drug. 
For cisplatin, quantification of drugs in nanoparticles and free drug was performed using 
inductively coupled plasma mass spectrometry (ICP-MS) and UV-Visible spectroscopy after 
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reaction with OPDA [16]. Amicon centrifugal filters were used to separate free drug from drug 
loaded in nanoparticles by centrifugation at 5000 rpm for 30 min. The filtrate was collected and 
the amount of free drug was determined by UV-Visible spectroscopy after addition of an equal 
volume of 1.4 mg/mL OPDA solution in presence of DMF and heating at 100 oC for 30 min. The 
resulting light-blue platinum-OPDA complex was detected at 705 nm by UV-Visible 
spectroscopy. ICP-MS analysis of the platinum concentration was conducted using a JY-24 
Sequential Spectrometer (Jobin Yvon) [17]. For DMC, the amounts of nanoparticle-loaded and 
free drug were determined though high-performance liquid chromatography (HPLC) on a 1200 
series HPLC system (Agilent Technologies) with a C18 column (Zorbax eclipse, 5 µm, 4.6 × 
 
2.7. Characterization of Nanoparticles: 
The size and zeta potential of nanoparticles in PBS buffer were determined by dynamic light 
scattering (DLS) and zeta potential analysis using a Beckman Coulter DLS instrument. The 
morphology of dried nanoparticles was examined using a JEOL 6700 scanning electron 
microscope (SEM). Samples for SEM were prepared by diluting nanoparticle suspension 
immediately after preparation to 0.05% (w/v) with ddH2O and placing a drop on a clean silicon 
wafer, followed by drying and platinum sputtering. Transmission electron microscopy (TEM) 
analyzes were conducted using a JEOL 2100. Samples for TEM were prepared by diluting the 
nanoparticle suspension immediately after preparation to 0.1% (w/v) with ddH2O, followed by 
application to a carbon-coated 200-mesh copper grid. 
2.8. In vitro Release of DMC and CDDP from CHC-Based Nanoparticles: 
In vitro drug release tests were conducted by dissolving nanoparticles in PBS at pH 5.5 and pH 
7.4 (final concentration of DMC, CDDP and CHC was 100 µg/mL, 200 µg/mL and 0.05 wt%, 
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respectively). The solutions were divided into 1.5 mL Eppendorf tubes, 3 for each time point. 
The tubes were gently shaken at 37 oC in an orbital shaker incubator. At predetermined times (4, 
8, 12, 24, 42 and 48 h) the released (free) drugs were separated from nanoparticles loaded with 
drugs by centrifugation. For DMC samples were centrifuged at 1000 rpm for 2 min and the pellet 
consisting of the precipitated released DMC was analyzed. For CDDP samples were filtered 
using Amicon centrifugal filters at 5000 rpm for 30 minutes and the filtrate containing released 
CDDP was analyzed. The concentrations of DMC and CDDP were quantified by HPLC and 
ICP-MS, as described above in the encapsulation efficiency section. The percentages of DMC 
and CDDP released at each time were calculated from the following equation: 
Released drug (%) = [(released drug) / (initial amount of drug)] X100   (2) 
2.9. Cell Culture:  
A549-ON and A549 cells were cultured in DMEM medium with 10% fetal bovine serum and 
were incubated under 5% CO2 and 37 oC [9]. The culture medium was renewed every two days 
and the cells were sub-cultured by trypsin-EDTA treatment. 
2.10. Cellular Uptake 
Cell internalization of nanoparticles by A549-ON and A549 cells was analyzed as follows. The 
investigated nanoparticles were loaded with the hydrophobic fluorescent reporter substance 
PSVue, which due to its hydrophobicity enters the CHC nanoparticles. 106 cells were plated in a 
100 mm dish and were allowed to attach for 24 hrs. To examine the effect of incubation time on 
nanoparticles internalization, the cells and nanoparticles (at 0.05 wt% CHC concentration) were 
suspended together in the medium for various time times (0.5, 1, 2, 4 h) at 37 °C. Free or 
nanoparticle loaded PSVue was used at a concentration of 100 µg/mL. After the incubation the 
cells were washed twice with PBS and were collected by trypsinization. Subsequently the cells 
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were centrifuged, dehydrated with 70% ethanol overnight at -20 °C and re-suspended in PBS at 
106 cells/mL. To avoid cell aggregation, the cell solutions were filtered through a nylon 
membrane (BD Biosciences, USA). The cellular uptake of PSVue was determined using a BD 
FACS Calibur flow cytometer (BD Biosciences) and the fluorescence intensity was quantified 
with CellQuest Pro software (BD Biosciences). A minimum of ten thousand cells were analyzed. 
2.11 In Vitro Cytotoxicity 
The cytotoxicity of DMC, free CDDP, free DMC and CDDP combo, CHC/DMC nanoparticles, 
CHC/CDDP nanoparticles, CHC/DMC-CDDP nanoparticles and CHC/DMC-CDDP/anti-CD133 
nanoparticles against A549-ON and A549 cells was evaluated by MTT colorimetric assay as 
follows: Cells were plated at 2 × 104 cells per well in a 24-well culture plate (Corning, USA) for 
attachment, followed by replacement of the medium with drug containing medium and 
incubation for 24h. Subsequently the medium was removed and the wells were washed twice 
with PBS. Then, MTT solution (0.5 mg/mL) was added followed by incubation for 4 h. The 
purple formazan was solubilized with isopropanol and cell viability was assessed by measuring 
the absorbance at 595 nm using a microplate reader (TECAN Sunrise, Switzerland). 
For A549-ON cells, the following drug dosages were used: Free drugs (as single or dual drug 
solution) [DMC] = 0, 3.25, 7.5, 15 and 20 µg/mL, [CDDP] = 0, 75, 150, 300 and 600 µg/mL; 
CHC/DMC nanoparticles [DMC] = 2.5, 5, 10, 15, and 20 µg/mL; CHC/CDDP nanoparticles 
[CDDP] = 50, 100, 200, 400, 800 µg/mL; CHC/DMC-CDDP and CHC/DMC-CDDP/anti-
CD133 nanoparticles [DMC] = 0, 1.25, 3, 5, 6 and 9 µg/mL, [CDDP] = 0, 95, 125, 200, 250, 265 
µg/mL.  
For A549 cells, the following drug dosages were used: Free drugs (as single drug solution) 
[DMC] = 0, 3.25, 7.5, 15 and 20 µg/mL, [CDDP] = 0, 12.5, 25, 50, 100 and 200 µg/mL; Free 
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drugs (as dual drug solution) [DMC] = 0, 1.25, 2.5, 5 and 10 µg/mL, [CDDP] = 0,  25, 50, 75 
and 100 µg/mL; CHC/DMC nanoparticles [DMC] = 2.5, 5, 10, 15, and 20 µg/mL; CHC/CDDP 
nanoparticles [CDDP] = 0, 12.5, 25, 50, 100 and 200 µg/mL; CHC/DMC-CDDP nanoparticles 
[DMC] = 0, 1.25, 2.5, 5 and 10 µg/mL, [CDDP] = 0,  25, 50, 75 and 100 µg/mL. 
Cytotoxicity data was analyzed to determine IC50 and synergy using CompuSyn and and Chou-
 [18]. 
 
3. Results 
3.1. Preparation of CDDP-Loaded CHC Nanoparticles and Characterization of CHC-CDDP 
Interactions 
It has been previously shown that cyto- and biocompatible [19, 20] CHC can effectively 
encapsulate and deliver DMC to lung cancer cells [21]. Thus the initial focus was to establish 
effective loading/modification of CHC with CDDP. Simple mixing of CDDP in 1% DMSO in 
ddH2O with CHC in ddH2O at pH 7 resulted in CDDP-loaded nanoparticles (CHC/CDDP) with 
EE of up to 65%, as determined by ICP-MS. XPS analysis confirmed the presence of CDDP in 
the nanoparticles. The shift of the Pt 4f peak towards higher binding energies (Fig. 1A, B) and 
the decrease in Cl:Pt ratio from about 2 for CDDP to about 1 for CHC/CDDP indicated binding 
of CDDP with CHC through replacement of chlorine in CDDP with a bond to oxygen, as 
described in literature [22]. The bond formation was further supported by changes in FTIR 
spectrum, where in particular the C-O stretch at 1209 cm-1 in CHC disappeared for CHC/CDDP 
(Fig. 1C).  
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Fig. 1. Confirmation of chemical bond formation in CHC/CDDP through XPS and IR. (A) XPS 
spectra of free CDDP, CHC and CHC/CDDP. (B) Pt signals at 74 eV and 78 eV from XPS 
analysis of free CDDP, CHC, and CHC/CDDP. (C) IR spectra of CHC and CHC/CDDP. 
 
Additional evidence for the formation of a chemical bond between CDDP and CHC through 
replacement of chlorine with oxygen was provided by 195Pt NMR, where chemical shifts of 2101 
ppm and 1849 ppm were recorded for CDDP and CHC/CDDP, respectively (Fig. 2), in 
agreement with literature [23, 24]. Combined the results prove that CDDP formed bonds with the 
carboxylic acid oxygen of CHC through replacement of chlorine. 
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Fig. 2. 195Pt NMR (600 MHz) analysis of CDDP, CHC and CHC/CDDP in D2O. Recorded 
chemical shifts were 2101 ppm for CDDP and 1849 ppm for CHC/CDDP. No signal was 
observed for pure CHC. 
 
3.2. Preparation and Characterization of Single/Dual-Drug Loaded and Biofunctionalized 
CHC Nanoparticles 
Nanoparticles incorporating both DMC and CDDP (CHC/DMC-CDDP) were again prepared 
by simple mixing of the drugs in 1% DMSO in ddH2O with CHC in ddH2O at pH 7, resulting in 
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EE of up to 50% and 60% for DMC and CDDP, respectively. Surface modification with CD133-
antibodies to form CHC/DMC-CDDP/anti-CD133 nanoparticles was achieved by addition of the 
antibodies, mixing at 4 oC and addition of EDC crosslinker followed by further mixing, all in one 
pot without purification steps. See Scheme 1 for conceptual drawing of the process. 
 
Scheme 1. Drawing illustrating the components and steps involved in the one-pot preparation of 
CHC/DMC-CDDP/anti-CD133 nanoparticles. 
 
TEM analysis revealed sub-100 nm sizes of bare CHC and CHC/CDDP nanoparticles, while 
nanoparticles containing DMC were above 100 nm in size. It was also found that CDDP alone 
distributed in nanometer-sized clusters through the CHC nanoparticle. Furthermore, CHC/DMC-
CDDP/anti-CD133 nanoparticles presented a distinct core loaded with CDDP and DMC and a 
shell-like feature seemingly without drugs (Fig. 3A-C; additional TEM images in supplementary 
material Fig. S1). SEM confirmed the CHC/DMC-CDDP/anti-CD133 nanoparticles to have a 
narrow size distribution in the 100-200 nm range (Fig. 3D). The nanoparticle sizes observed 
 15 
using electron microscopy agreed well with those acquired in PBS using DLS for each 
preparation (Table 1). The anti-CD133 modified particles presented a slight negative zeta 
potential -3 mV in PBS, see Table 1 for details on zeta potential for each preparation) while 
maintaining good colloidal stability. 
 
Fig. 3. Electron microscopy images of different nanoparticle preparations. TEM image of 
individual nanoparticle for (A) CHC, (B) CHC/DMC-CDDP, (C) CHC/DMC-CDDP/anti-
CD133. (D) SEM image of CHC/DMC-CDDP/anti-CD133 nanoparticles. 
 
Table 1. Hydrodynamic diameter from DLS and zeta potential of different formulations in pH 
7.4 PBS. One standard deviation is given within parentheses (n = 3). 
Sample D (nm) Zeta Potential (mV) 
CHC 50 (10) -22 (0.65) 
CHC/DMC 130 (21) -9 (1.1) 
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CHC/CDDP 75 (12) -21 (2.7) 
CHC/DMC-CDDP 150 (20) -6 (2.3) 
CHC/DMC-CDDP/anti-
CD133 
190 (17) -3 (1.0) 
 
3.3 In Vitro Drug Release 
The in vitro release of CDDP and DMC from different preparations in pH 5.5 (relevant to 
lysosomes) and pH 7.4 PBS buffer was determined over 48 h. As seen in Fig. 4 there was a 
general trend that dual-drug loading and anti-CD133 modification reduced the drug release rate 
and the amount of drug released at the plateaus in the release curves. The exception was the 
release of CDDP at pH 5.5, which was similar for all preparations. For the CHC/DMC-
CDDP/anti-CD133 nanoparticles, being the preparation in focus, only about 10% of DMC and 
14% of CDDP was released over the 48 h of the experiment at pH 7.4. At pH 5.5 the 
corresponding numbers were about 20% and 30% for DMC and CDDP, respectively. 
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Fig. 4. In vitro cumulative release profile of DMC and CDDP from CHC/DMC, CHC/DMC-
CDDP and CHC/DMC-CDDP/anti-CD133 nanoparticles in PBS buffer with pH 5.5 or 7.4 at 37 
oC; (A) DMC - pH 7.4, (B) DMC - pH 5.5, (C) CDDP - pH 7.4 and (D) CDDP - pH 5.5. Each 
data point is presented as mean ± SD (n = 3), where no error bars are visible the SD was smaller 
than the symbols. 
 
3.4. Cell Uptake 
It was confirmed in vitro, using PSVue as a fluorescent reporter substance, that CHC 
nanoparticles improved cell internalization by stem-like A549-ON lung cancer cells and that the 
anti-CD133 modification enhanced the cell uptake even further, achieving an uptake ratio of 1.3 
relative to free PSVue after 4 hours. It was further demonstrated that the uptake of anti-CD133 
 18 
nanoparticles was significantly higher for the A549-ON cells compared to native A549 cells 
(Fig. 5). 
 
Fig. 5. In vitro cellular uptake of free PSVue, CHC/PSVue and CHC/PSVue/anti-CD133 
nanoparticles by A549-ON cell after incubation for 0, 0.5, 1, 2 and 4 h. Uptake of 
CHC/PSVue/anti-CD133 by native A549 cells is included for comparison. Each data point is 
presented as mean ± SD (n = 3). Double-star (**) indicate significance (p-value <0.01). 
 
3.5. In Vitro Cytotoxicity 
In vitro cell assays revealed that CHC nanoparticles improved the cytotoxicity of DMC and 
CDDP against A549-ON and A549 cells. For A549-ON cells the IC50 values of free DMC, 
CHC/DMC, free CDDP and CHC/CDDP after 24 hours of incubation were calculated to 11, 6.0, 
297 and 242 µg/mL (33, 18, 990 and 810 µM), respectively. The IC50 values against native A549 
cells were determined to 11.8, 6.1, 124.9 and 33.1 (35, 18, 416 and 110 µM) for free DMC, 
CHC/DMC, free CDDP and CHC/CDDP, respectively (Table 2). The results highlight the 
resistance of A549-ON cells against CDDP. Furthermore, the increase in drug potency from 
encapsulation into the CHC nanoparticles was similar between the cell lines for DMC, while for 
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CDDP the result differed greatly between the cell lines. The encapsulation only resulted in a 
slight lowering of the IC50 value for A549-ON cells while the IC50 for native A549 cells was 
decreased from 124.9 µg/mL to 33.1 µg/mL. 
 
Table 2. IC50 for treatment of A549 and A549-ON cells with DMC or CDDP as free drugs or in 
CHC nanoparticles. 
Drug (µg/mL)  
Cell line 
DMC CDDP CHC-DMC CHC-CDDP 
A549 11.8 124.9 6.1 33.1 
A549-ON 11 297 6.0 242 
 
The synergy between DMC and CDDP as free drugs, in CHC nanoparticles and in CHC/anti-
CD133 nanoparticles, was investigated utilizing a Chou- -CI plot) [18], shown 
in Fig. 6A. Briefly, on the Y-axis the combination index (CI) is shown for different 
concentrations of the two drugs, with the corresponding effects (Fa) being shown on the X-axis. 
CI values less than one, equal to one and more than one indicate synergistic, additive and 
antagonistic drug effects, respectively. Against A549-ON cells all concentrations of free DMC 
and CDDP were indicated to be antagonistic in their effects. In contrast, when loaded into CHC 
nanoparticles synergy was observed for high Fa, i.e., the two dual-drug combinations with 
highest concentration ([DMC] = 6 and 9 µg/mL; [CDDP] = 250 and 265 µg/mL). When loaded 
into the CD133-targeted CHC nanoparticles even stronger synergistic effect was observed at 
even lower Fa, i.e., starting at lower drug concentrations ([DMC] = 5 µg/mL and [CDDP] = 200 
µg/mL). In contrast to the results for MDR A549-ON cells, for native A549 cells similar degree 
of synergy was observed both for free drugs and drugs loaded in the CHC/DMC-CDDP 
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nanoparticles, with free drugs even presenting higher degree of synergy at the lowest 
concentrations (Fig. S3). The degree to which the targeting increased cytotoxicity of the dual-
loaded drugs against MDR A549-ON cells is also clear when comparing the cell viability after 
exposure to different drug concentrations from CHC/DMC-CDDP or CHC/DMC-CDDP/anti-
CD133 nanoparticles for 24h. 
As seen in Fig. 6B the cell killing was much improved even at lower concentrations for the 
targeted nanoparticles, as compared to the non-targeted ones. At the highest investigated 
concentration of drugs ([DMC] = 9 µg/mL and [CDDP] = 265 µg/mL) the cell viability was as 
low as 4% for CHC/DMC-CDDP/anti-CD133 while it was 23% for CHC/DMC-CDDP. Control 
experiments using CHC or CHC/anti-CD133 nanoparticles without drugs revealed that both 
nanoparticles presented negligible effect on cell viability of A549-ON cells (Fig. S2).  
 
Fig. 6. In vitro cytotoxicity of A549-ON treated with various drug combinations for 24 hours. 
(A) The Chou-Talalay  Plot for A549-ON cells treated with free dual drugs, CHC/dual-drug 
nanoparticles and CHC/dual-drug/anti-CD133 nanoparticles for 24 hrs. (B)The cell viability of 
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A549-ON cells treated with different dosages of CHC/dual-drug nanoparticles and CHC/dual-
drug/anti-CD133 nanoparticles for 24 hrs. Each data point is presented as mean ± SD (n = 3). 
The double-star (**) indicate significance (p-value <0.01). 
 
4. Discussion 
CHC nanoparticles loaded with the dual drugs DMC and CDDP and modified with antibodies 
for targeting of the CSC surface marker CD133 (CHC/DMC-CDDP/anti-CD133) were 
successfully prepared by a one-pot synthesis at room temperature in water, involving only small 
amounts of the benign solvent DMSO. The nanoparticles achieved greatly increased synergy 
between the drugs in vitro. The feasible preparation was ascribed to the fact that CHC presents 
nano-microenvironments that can house both hydrophilic and hydrophobic substances [25]. As 
discussed in section 3.1 and shown from analyses (Fig. 1 and 2) the hydrophilic CDDP became 
chemically bound to carboxylic acid oxygens of CHC, which explains the effective and stable 
loading of this hydrophilic substance. The subsequent controlled release of CDDP was explained 
by replacement of the carboxylic acid ligands of CHC with water or chloride [22]. Although 
CDDP is highly water soluble EE of up to 60% was achieved during dual-drug loading in 
aqueous solution and only about 14% of the drug was released during in vitro release studies in 
PBS with pH = 7.4 (Fig. 4C). For DMC the low chemical potential in the hydrophobic domains 
of CHC nanoparticles, compared to in water (very low water solubility), was enough to achieve 
stable drug loading and controlled release. The EE for DMC in the dual-drug loaded particles 
was up to 50% and only about 10% of the drug was released during the in vitro release studies in 
PBS with pH = 7.4 (Fig. 4A). The high EE for both drugs and the very limited escape of the 
drugs at pH 7.4 indicated that the CHC nanoparticles would retain the drug in 
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circulation/extracellular space, offering potential for simultaneous delivery of the drugs after 
internalization by cells in endo/lysosomes. It was found that the amounts of released drugs 
increased slightly at pH 5.5, but 70% and 80% still remained in the nanoparticles for CDDP and 
DMC, respectively (Fig. 4B, D). It was thus concluded that the drug loading in the particles was 
highly stable and even under lysosome-relevant pH of 5.5 drug release by passive diffusion out 
from the particles would be marginal. However, from our previous work it was known that CHC 
is degraded by lysozyme [20, 21]. It was expected that intracellular release would be triggered to 
some extent by this enzymatic degradation once the nanoparticles had been internalized by the 
cells and ended up in endosomes or lysosomes [21], ensuring simultaneous intracellular delivery 
of both drugs at accelerated release rate for enhanced synergistic effect.  
Evaluation of different preparations of the drugs and CHC nanoparticles, with/without CD133-
targeting, in cell assays using highly malignant and MDR A549-ON lung CSC [9, 10] revealed 
that CD-133 targeting modification corresponded with increased cell uptake and that uptake of 
the targeted nanoparticles was higher by A549-ON cells than by native A549 cells (Fig. 5). 
Furthermore, the CHC/DMC-CDDP/anti-CD133 nanoparticles greatly enhanced the synergistic 
effects between the drugs against MDR A549-ON (Fig. 6), while against native non-MDR A549 
cells the synergy was comparable between free drugs and drugs loaded in the functionalized 
nanoparticles (Fig. S3). This is in contrast to a recent study in which no improvement (possibly 
some reduction) in combined cytotoxicity was observed in vitro for combinations of 
CDDP/polymer-conjugated nanoparticles and free curcumin against CDDP-resistant ovarian 
cells, compared to when using combinations of the free drugs at the same concentrations [14]. 
Likely the greatly improved synergy by CHC/DMC-CDDP/anti-CD133 nanoparticles in the 
present study was due to effective cell internalization and simultaneous intracellular release of 
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the two drugs, which in turn enabled suppression of MDR and effective cell killing (see Scheme 
2). However, it is recognized that the increase in cell uptake with the anti-CD133 modification 
was moderate and likely there were additional underlying mechanisms that contributed to the 
greatly enhanced synergy. Those mechanisms and detailed cell-biological responses to the 
CHC/DMC-CDDP/anti-CD133 nanoparticles would be an interesting topic for a future study. 
The outstanding degree to which the CHC/DMC-CDDP/anti-CD133 nanoparticles mediated 
synergy between DMC and CDDP becomes further evident by comparing their cytotoxicity 
against the A549-ON cells after 24 h with that of dual-administered free drugs at similar drug 
concentrations. For example, for administration of 15 µg/mL of DMC and 300 µg/mL CDDP as 
free drugs the cell viability was about 28% after 24 h, while for administration of 9 µg/mL of 
DMC and 265 µg/mL CDDP in CD133-targeting CHC nanoparticles the viability was as low as 
4% (Fig. S4). Further indication of the potency of the CHC/DMC-CDDP/anti-CD133 
nanoparticle system against the MDR A549-ON lung CSC is given by comparing the 
cytotoxicity at a CDDP concentration similar to the IC50 concentrations of free CDDP and 
CDDP/CHC, which were 297 and 242 µg/mL, respectively. At a similar CDDP concentration of 
265 µg/mL the CHC/DMC-CDDP/anti-CD133 with 9 µg/mL DMC all but eradicated the A549-
ON cells. This is especially impressive given that the viability of CDDP-resistant A549 cells has 
been found to plateau at a viability of about 40% with increasing CDDP concentration [26] and 
that in another study the inhibition was only about 40% when such cells were incubated with 200 
µg/mL CDDP for 24 h [27]. The ability of the CHC/DMC-CDDP/anti-CD133 nanoparticle 
system to kill close to all cancer cells is highly relevant for improved treatments as it is 
considered that in the clinic insufficient killing of tumors may result in cancer relapse with cells 
having pre-existing or acquired drug resistance. 
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Scheme 2. Illustration of how the CHC/DMC-CDDP/anti-CD133 nanoparticles enter the cells 
and how the drugs act in synergy to overcome MDR. 
 
With regard to opportunities to formulate the nanoparticles for clinical administration; the size 
and zeta potential analyses revealed sizes < 200 nm and a slightly negative zeta potential of -3 
mV for the CHC/DMC-CDDP/anti-CD133 nanoparticles (Fig. 3 and Table 1). Such size and zeta 
potential indicate promise for circulating nanoparticles targeting the leaky vasculature in vicinity 
of tumors [28], i.e., the EPR-effect. Although, since the focus of the system is lung cancer, direct 
administration to cancerous lung tissue or lymph nodes via inhalation [29-31] and injection [32] 
are also interesting opportunities to consider when developing and formulating the particles for 
further evaluation in disease relevant models.  
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To conclude, the outstanding efficacy of the CHC/DMC-CDDP/anti-CD133 nanoparticles 
against stem-like lung cancer cells, highly feasible one-pot preparation, colloidal properties and 
previously demonstrated biodegradation and biocompatibility of CHC [19, 20] indicate that the 
system has clear potential as a dual-drug nanomedical approach to battle multidrug resistant lung 
cancer, including the elusive stem-like cancer cells. Further investigations using an in-vivo lung 
tumor model is currently under development for this dual-drug biofunctionalized CHC 
nanoparticle technology and will be reported separately. 
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